In the SOLAR-1 study (NCT02437318), the combination of fulvestrant and alpelisib, an α-selective PI3K inhibitor, was compared with fulvestrant and placebo for patients with HR+/HER2− advanced BC with PIK3CA mutations who progressed during or after the treatment with AI. The gene discussed is HR; the disease is breast cancer.